XTX Topco’s Seres Therapeutics MCRB Stock Holding History

XTX Topco’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Buy	+20,732	New	+$158K	﹤0.01%	3350
2025 Q3	–	Sell	-22,417	Closed	-$249K	–	2982
2025 Q2	$249K	Buy	+22,417	New	+$197K	0.01%	1550
2025 Q1	–	Sell	-815	Closed	-$13.5K	–	2796
2024 Q4	$13.5K	Buy	+815	New	+$13.2K	﹤0.01%	2107
2024 Q3	–	Sell	-1,107	Closed	-$16K	–	2390
2024 Q2	$16K	Sell	1,107 -2,678	-71%	-$44.7K	﹤0.01%	1645
2024 Q1	$58.6K	Sell	3,785 -16,340	-81%	-$352K	0.01%	1447
2023 Q4	$564K	Buy	20,125 +12,620	+168%	+$331K	0.12%	195
2023 Q3	$357K	Buy	+7,505	New	+$573K	0.06%	610
2023 Q1	–	Sell	-1,952	Closed	-$219K	–	1509
2022 Q4	$219K	Buy	1,952 +1,385	+244%	+$186K	0.05%	789
2022 Q3	$73K	Buy	+567	New	+$58.1K	0.02%	990
2022 Q1	–	Sell	-579	Closed	-$97K	–	844
2021 Q4	$97K	Sell	579 -649	-53%	-$103K	0.05%	470
2021 Q3	$171K	Buy	+1,228	New	+$240K	0.06%	527

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

XTX Topco's MCRB Position: Q2 2026 in Review

XTX Topco opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 20,732 shares worth $164K. The stake represents ﹤0.01% of the portfolio and ranks #3350 among its holdings. This is a return to the name: XTX Topco previously reported a position in MCRB as recently as Q2 2025.

XTX Topco first reported a position in MCRB in Q3 2021 and has held it in 11 quarters since. The position peaked at $564K in Q4 2023. 36 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

XTX Topco held 20,732 shares of Seres Therapeutics worth $164K as of Q2 2026.
Seres Therapeutics was a new XTX Topco position in Q2 2026.
Seres Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3350 holding.
XTX Topco first reported a position in Seres Therapeutics in Q3 2021 and has held it in 11 quarters since.
XTX Topco's Seres Therapeutics position peaked at $564K in Q4 2023.
36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.